Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2019
Price :
$35
*
At a glance
- Drugs Tradipitant (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- Sponsors Vanda Pharmaceuticals
- 31 Oct 2017 Status changed from recruiting to completed.
- 02 Oct 2017 Data from this trial will be presented at the 9th World Congress of Itch (2017), according to a Vanda Pharmaceuticals Inc. media release.
- 13 Sep 2017 Primary endpoint has not been met. (Efficacy of tradipitant relative to placebo in reducing chronic pruritus as measured by the Visual Analogue Scale (VAS).), according to a Vanda Pharmaceuticals media release